Skip to main content
. 2015 Apr 17;10(4):e0118485. doi: 10.1371/journal.pone.0118485

Table 3. Patient/Disease Characteristics of the BM Training, Verification and Validation Analysis Sets.

Patient/Disease Characteristics Subgroups BM Training Analysis Set (n = 43) BM Validation Analysis Set (n = 42) P b BM Verification Analysis Set (n = 24)
Response to induction therapy a RD 12 10 0.92 12
CR/CRi without CCR1 19 20 12
CCR1 12 12 0
Age (Years) (Min, Max), Median (56.8, 83.9), 68.2 (58.0, 82.0), 69.0 0.98 (57, 80), 69
Cytogenetic risk group Better 4 2 0.86 0
Intermediate c 26 25 10
Poor 6 8 5
Missing 7 7 9
FLT3 ITD Mutant 8 10 0.60 4
Wildtype 35 32 17
Unknown 0 0 3
Sex F 16 15 1.00 9
M 27 27 15
AML onset De novo 38 34 0.38 17
Secondary 5 8 7
WBC (10 9 /L) (Min, Max), Median (1.3, 263.0), 33.2 (1.4, 274.0), 19.1 0.62 (1.6, 120.2), 28.6
Percent Health at 15 mins (Min, Max), Median (26.0, 87.2), 52.2 (31.8, 86.3), 60.0 0.077 (29.8, 79.76), 50.4

a) CR = complete response; CRi = complete response with incomplete peripheral blood recovery; CCR1 = CR/CRi with duration > 1 yr; RD = resistant disease.

b) P-value for comparison of BM Training and BM Validation Analysis Sets.

c) Includes patients with known karyotype of indeterminate risk classification.